Take a look at the therapies that have already reached the market.
Arctic Vision partners with Santen Pharmaceutical Co., Ltd. to commercialise ARVN001 in China
ARVN001 is indicated for the treatment of uveitic macular oedema and certain other ophthalmic indications
PHOTON Results and Their Relation to DME Patients in Your Practice
John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.
European Commission approves aflibercept biosimilar OPUVIZ (previously SB15) from Samsung Bioepis
OPUVIZ, previously known as the biosimilar candidate SB15, has been approved for the treatment of nAMD, DME and other retinal diseases
PULSAR Results and Their Relation to nAMD Patients in Your Practice
John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.
US FDA issues Complete Response Letter for avacincaptad pegol (Izervay, Astellas Pharma Inc)
The CRL comes in response to a supplemental New Drug Application for Izervay, a treatment for geographic atrophy secondary to age-related macular degeneration
NHS introduces OCT programme to reduce annual hospital visits for patients with diabetes
Optical coherence tomography will be in all eye care services by October 2025
